InsiderTrades.com logo
The asset beating inflation by 4x
From Colonial Metals   |   Ad
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
That's why we have released our Free Precious Metals Investment Guide that explains all the details
Yutaka Niihara net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Yutaka Niihara Biography and Net Worth

CEO of Emmaus Life Sciences
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease. He is a cofounder of Emmaus, principal investigator for LABioMed at Harbor-UCLA Medical Center and Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.

His experience includes serving as President, Chief Executive Officer and Medical Director of Hope International Hospice. Board-certified by the American Board of Internal Medicine and the American Board of Internal Medicine/Hematology, Dr. Niihara is licensed to practice medicine in both the U.S. and Japan. His honors include the Life Time Achievement Award, from the Sickle Cell Disease Foundation of California and the Abigail Kawananako Award. Dr. Niihara received his B.A. in Religion from Loma Linda University, obtained his M.D. degree from the Loma Linda University School of Medicine in 1986, and received his MPH from Harvard School of Public Health in 2006.

How do I contact Yutaka Niihara?

The corporate mailing address for Dr. Niihara and other Emmaus Life Sciences executives is 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503. Emmaus Life Sciences can also be reached via phone at (310) 214-0065 and via email at [email protected]. Learn More on Yutaka Niihara's contact information.

Has Yutaka Niihara been buying or selling shares of Emmaus Life Sciences?

Yutaka Niihara has not been actively trading shares of Emmaus Life Sciences over the course of the past ninety days. Most recently, on Friday, May 14th, Yutaka Niihara bought 12,800 shares of Emmaus Life Sciences stock. The stock was acquired at an average cost of $1.22 per share, with a total value of $15,616.00. Learn More on Yutaka Niihara's trading history.

Yutaka Niihara Insider Trading History at Emmaus Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2021Buy12,800$1.22$15,616.00
5/10/2021Buy6,000$1.20$7,200.00
10/13/2020Buy4,500$0.88$3,960.00
10/8/2020Buy1,500$1.02$1,530.00
10/1/2020Buy9,750$0.99$9,652.50
9/28/2020Buy3,500$1.02$3,570.00
6/15/2020Buy1,500$1.67$2,505.00
6/5/2020Buy5,700$1.74$9,918.00
6/3/2020Buy6,000$1.60$9,600.00
6/1/2020Buy5,700$1.65$9,405.00
5/28/2020Buy2,700$1.57$4,239.00
5/26/2020Buy1,600$1.37$2,192.00
5/21/2020Buy5,700$1.37$7,809.00
5/15/2020Buy1,900$1.35$2,565.00
5/13/2020Buy5,300$1.29$6,837.00
5/8/2020Buy7,850$1.24$9,734.00
5/6/2020Buy4,000$1.20$4,800.00
5/4/2020Buy8,000$1.33$10,640.00
4/7/2020Buy13,000$1.25$16,250.00
4/2/2020Buy30,800$1.25$38,500.00
3/30/2020Buy19,200$1.34$25,728.00
3/18/2020Buy7,200$1.61$11,592.00
3/10/2020Buy42,850$1.70$72,845.00
3/5/2020Buy23,750$1.61$38,237.50
2/21/2020Buy48,000$1.89$90,720.00
2/18/2020Buy22,750$1.72$39,130.00
2/12/2020Buy31,100$1.75$54,425.00
2/7/2020Buy18,800$1.70$31,960.00
10/31/2019Buy5,500$3.10$17,050.00
10/18/2019Buy7,000$2.75$19,250.00
10/15/2019Buy19,100$2.48$47,368.00
9/25/2019Buy10,000$2.13$21,300.00
9/23/2019Buy40,000$5.04$201,600.00
9/6/2019Buy32,499$4.03$130,970.97View SEC Filing Icon  
8/29/2019Buy20,000$3.19$63,800.00View SEC Filing Icon  
8/27/2019Buy31,700$2.76$87,492.00View SEC Filing Icon  
8/21/2019Buy19,500$3.38$65,910.00View SEC Filing Icon  
See Full Table

Yutaka Niihara Buying and Selling Activity at Emmaus Life Sciences

This chart shows Yutaka Niihara's buying and selling at Emmaus Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Emmaus Life Sciences Company Overview

Emmaus Life Sciences logo
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Read More

Today's Range

Now: $0.10
Low: $0.10
High: $0.10

50 Day Range

MA: $0.11
Low: $0.09
High: $0.13

2 Week Range

Now: $0.10
Low: $0.05
High: $0.33

Volume

2,200 shs

Average Volume

19,331 shs

Market Capitalization

$6.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61
The asset beating inflation by 4x
From Colonial Metals   |   Ad
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
That's why we have released our Free Precious Metals Investment Guide that explains all the details